• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5651
    • Acute Myelogenous Leukemia 200
    • Bladder Cancer 67
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 223
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 106
    • COVID-19 27
    • Gastrointestinal Cancer 88
    • General 319
    • Head and Neck Cancers 72
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 153
    • Kidney Cancer 374
    • Liver Cancer 25
    • Lymphoma 179
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 458
    • Myeloproliferative Disease 19
    • News 147
    • Non-Hodgkin Lymphoma 76
    • Non-Small Cell Lung Cancer 409
    • Other 241
    • Ovarian Cancer 43
    • Pancreatic Cancer 72
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 218
    • Sickle Cell 21
    • Small Cell Lung Cancer 71
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 2
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    Current treatment landscape in classical MPNs
    00:01:53

    Current treatment landscape in classical MPNs

    The treatment landscape for myeloproliferative neoplasms (MPNs) is constantly evolving, as Ruben Mesa, MD, of UT Health San Antonio Cancer Center, San Antonio, TX, explains in this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. He discusses new standardized guidelines for managing MPN patients, and controlling the symptoms and risk of thrombosis. He also gives an overview of the newest clinical trial developments in the field, mentioning the use of ruxolitinib in both polycythemia vera and myelofibrosis, before finally highlighting the potential for combining ruxolitinib with PI3K inhibitors for more effective treatment.

    157 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Trending

    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
    00:02:31

    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials

    Free
    38 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug
    00:02:32

    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug

    Free
    52 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2
    00:13:43

    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

    Free
    238 Views
    2 years ago
    PVReporter
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter
    00:08:25

    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter

    Free
    140 Views
    2 years ago
    PVReporter
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5

    Myeloproliferative Disease

    Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-M... Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-M...
    0:07:07

    Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-M...

    Free
    7 Views
    3 months ago
    AACR
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    COVID-19 & Hematologic Malignancies: Episode 6 - Myeloid Malignancies Update
    00:23:13

    COVID-19 & Hematologic Malignancies: Episode 6 - Myeloid Malignancies Update

    Free
    8 Views
    6 months ago
    HMP CME
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD
    0:02:32

    Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD

    Free
    9 Views
    1 year ago
    ash
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD
    0:03:24

    A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD

    Free
    27 Views
    1 year ago
    ash
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
    00:02:31

    Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials

    Free
    38 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug
    00:02:32

    How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug

    Free
    52 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2
    00:13:43

    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

    Free
    238 Views
    2 years ago
    PVReporter
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter
    00:08:25

    Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter

    Free
    140 Views
    2 years ago
    PVReporter
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter
    00:15:02

    Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter

    Free
    165 Views
    2 years ago
    PVReporter
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning
    00:01:06

    Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning

    Free
    120 Views
    2 years ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Personalized Model for Allogeneic Hematopoietic Stem Cell Patients with Myelodysplastic Syndromes
    00:02:11

    Personalized Model for Allogeneic Hematopoietic Stem Cell Patients with Myelodysplastic Syndromes

    Free
    127 Views
    2 years ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Somatic mutations in MDS as a diagnostic and prognostic tool
    00:02:44

    Somatic mutations in MDS as a diagnostic and prognostic tool

    Free
    120 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592